bioRxivPharmacology & ToxicologyPreprint
Transcriptomic insights into early diagnosis of doxorubicin-induced cardiotoxicity in a rat model
Emilia AncaiD, Ilie-Ovidiu PaveliD, Emilia LicăreteiD, C RoşioruiD, Camelia DobreiD, Manuela BanciuiD
Abstract
Doxorubicin is a member of the anthracycline class of chemotherapeutic agents and is among the most effective treatments available up to date. However, its clinical use is significantly limited by severe cardiotoxic effects. The purpose of this study is to investigate the transcriptomic alterations that occur in a rat model of doxorubicin-induced cardiotoxicity. Our results reveal significant dysregulations of cardiac metabolism and provide insights into the molecular mechanisms underlying cardiac damage produced by this treatment. Our analysis revealed that heart tissue recovery following doxorubicin treatment is hindered by hypercholesterolemia exacerbated by transcriptomic-level alteration of the circadian rhythm. This result could help facilitate the discovery of circulating biomarker-based early diagnostic methods for this disease, along with cardioprotective treatment implementation.
- organism: rat
- assay: bulk RNA-seq
- research focus: differential expression
- research focus: cell type annotation
- approach: statistical model
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Integrated Omics Approach to Delineate the Mechanisms of Doxorubicin-Induced Cardiotoxicity
Mohamed S. Dabour, Ibrahim Y. Abdelgawad, … Beshay N. M. Zordoky·PharmaceuticalsPeer-reviewed·Jan 29, 2026
- Doxorubicin-induced Cardiotoxicity is Propagated by Paracrine Signaling through Small Extracellular Vesicles
George Ronan, Lara Ece Celebi, … Pınar Zorlutuna·Acta BiomaterialiaPeer-reviewed·Aug 28, 2026
- Exercise prevents cardiac electrical remodeling in doxorubicin-treated female mice but does not provide cardioprotection in males.
Amber V Melcher, Lauren Haflett, … Sharon Ann George·bioRxiv·May 29, 2026
- Sex differences in cardiomyocyte proteomic responses to the cardiotoxic chemotherapy drug doxorubicin
Sanela Dozic, Michael G. Leeming, … Kate L. Weeks·bioRxiv·Apr 24, 2026
- ATF4 alleviates doxorubicin-induced cardiomyopathy through H2S-mediated antioxidation
Shuting Xu, Yan Shi, … Guangyu Zhang·bioRxiv·Sep 3, 2025
- Progressive suppression of DNA repair genes with persistent p53 activation in Doxorubicin-treated cardiomyocytes
Emma M Pfortmiller, José A Gutiérrez, … Michelle C. Ward·G3 Genes Genomes GeneticsPeer-reviewed·Jun 22, 2026